BPC-157: A Reconstitution Walkthrough

BPC-157 is the compound people most often reconstitute first, and the one most often described with more confidence than the evidence supports. This article does two separate things, in this order: the arithmetic, which is settled, and the evidence, which is not.

The two vial sizes you'll meet

BPC-157 is typically supplied as 5 mg or 10 mg of lyophilised powder. Both are handled identically — only the concentration differs.

10 mg vial, 2 mL of bacteriostatic water

• Concentration: 10 mg ÷ 2 mL = 5 mg/mL
• A 250 mcg dose = 0.25 mg ÷ 5 mg/mL = 0.05 mL = 5 units on a U-100 syringe
• Doses in the vial: 10 mg ÷ 0.25 mg = 40

Five units is readable on a 0.3 mL syringe but sits closer to the resolution floor than is ideal. If you find yourself squinting, that is the signal to use more diluent on the next vial rather than to try harder.

5 mg vial, 2 mL of bacteriostatic water

• Concentration: 5 mg ÷ 2 mL = 2.5 mg/mL
• A 250 mcg dose = 0.25 ÷ 2.5 = 0.1 mL = 10 units
• Doses in the vial: 5 mg ÷ 0.25 mg = 20

The 5 mg vial at the same diluent volume gives the more comfortable draw — 10 units is a clean, unambiguous mark. Half the doses per vial, but each one easier to measure correctly, which for most people is the better trade.

The comparison worth internalising

Note rows two and four: identical concentration, identical draw, different numbers of doses. The dose count is set by the milligrams in the vial; the draw size is set by the dilution. They are independent, and confusing them is the origin of most bad advice on this topic. Run your own numbers in the calculator.

Storage specifics

Per the library entry: the lyophilised powder is refrigerated; stable at room temperature for short periods. Reconstituted, refrigerate at 2–8°c. commonly cited as usable for ~30 days.

With a reported half-life of around hours, BPC-157 clears quickly, which is why protocols in the literature and in practice tend toward once or twice daily administration rather than weekly. Practically, a 40-dose vial dosed once daily is a 40-day run — longer than the ~30 day post-reconstitution window usually cited. That mismatch is the thing to plan around: either dose twice daily, split the dry powder across two vials before adding any water, or accept that the final doses are weaker than the first. The storage guide covers why that potency loss is invisible.

What the evidence actually shows

BPC-157 has a substantial preclinical literature — a large fraction of it from a single research group, led by Predrag Sikiric, over roughly three decades. Across rat and mouse models it has been reported to accelerate healing in tendon, ligament, muscle, bone, and gastrointestinal tissue, and to show effects on angiogenesis and on nitric-oxide pathways.

The limitations are as important as the findings:

• Almost entirely animal work. The healing results people cite are from rodents. Effects in rodent tendon do not reliably transfer to human tendon, and the history of regenerative medicine is largely a history of that gap.
• Very little human data. There have been early-phase safety studies, but there is no adequately powered randomised controlled trial demonstrating an efficacy outcome in humans for any injury indication. “No published RCT” is not the same as “doesn't work” — it means the question is open.
• Concentrated provenance. When most of a literature originates with one group, independent replication carries disproportionate weight, and there is comparatively little of it.
• Unknown long-term safety. Short-term tolerability in animals appears good, and no consistent toxicity signal has emerged. That is a much weaker statement than an established human safety profile. The angiogenic mechanism in particular has not been characterised for long-term human use.
• Oral bioavailability is unsettled. It is often described as orally active, which for a 15-amino-acid peptide facing gastric proteases is a strong claim. The supporting data is largely from the same preclinical body of work.

What to record

Whatever protocol you and a clinician arrive at, the log is what makes it interpretable later. Record the dose in micrograms, the concentration, the unit count, the injection site, and the reconstitution date of the vial it came from. A log reading “5 units” is meaningless once the next vial is mixed differently; “250 mcg — 5 u at 5 mg/mL, vial opened 12 Jun” still means something in six weeks, including whether the later doses came from a vial past its window.

Half-life, vial sizes, routes and storage for the other compounds in the library are listed the same way, with regulatory status stated on every one.